Clinical trials: PD, open to volunteers
Peritoneal Dialysis (PD), Large Language Models
A Simulated Case Study of a Peritoneal Dialysis-Specialized Large Language Model Assisting Doctors in Improving Decision-Making in Peritoneal Dialysis Management
This study is a randomized controlled trial based on simulated clinical cases, aiming to establish a standardized evaluation system for PD physicians, to assess the differences in PD management quality between a workflow assisted…
- Trial name
- NCT07724327
- Testing
- Peritoneal dialysis-specialized large language model.
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Parkinson Disease (PD)
Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs
Parkinson's disease (PD) is a progressive neurological condition that can affect movement, balance, endurance, and overall quality of life.
- Trial name
- NCT07221266
- Testing
- Guided Cycling, Non-Contact Boxing, Traditional Physical Therapy Program (Standard of Care)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Texas, El Paso
Acute Myeloid Leukemia
Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia
This is a prospective, multicenter, clinical-biological cohort study. Its objective is to assess the pharmacokinetics-pharmacodynamics (PK-PD) of venetoclax (VEN) in patients with Acute Myeloid Leukemia (AML).
- Trial name
- EUREKA-VEN (NCT07243483)
- Testing
- Pharmacokinetic dosages of venetoclax
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Leon Berard
Triple Negative Breast Cancer (TNBC), PD-L1 Positive
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
This is an open-label, single-arm, multicenter phase II study to evaluate the safety and efficacy of sac-TMT plus Tagitanlimab in patients with PD-L1-positive locally advanced or metastatic TNBC.
- Trial name
- NCT07153965
- Testing
- Sacituzumab Tirumotecan plus Tagitanlimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended…
- Trial name
- DeLLphi-313 (NCT07531095)
- Testing
- ZL-1310, Tarlatamab, Durvalumab
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Parkinsons Disease (PD)
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
Parkinson's disease (PD) is currently the fastest-growing neurological condition globally. It is projected to affect 172,000 people in the UK by 2030,with the current annual cost to the country being ~£3.6 billion.
- Trial name
- EJS ACT-PD (NCT07207057)
- Testing
- Telmisartan, Terazosin (Hytrin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- University College, London
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Advanced Non-Small Cell Lung Cancer
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06980272
- Testing
- SSGJ-707, Pembrolizumab
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Remimazolam, Pharmacokinetics and Pharmacodynamics
Efficacy and Safety of Eleveld PK/PD Model-based Dosing During General Anesthesia
The goal of this randomized, controlled clinical trial is to evaluate the efficacy, safety, and recovery profile of an individualized, Eleveld pharmacokinetic/pharmacodynamic model-guided dosing strategy for remimazolam in adult…
- Trial name
- NCT07675850
- Testing
- Eleveld model-guided dosing, Standard weight-based label dosing
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Triple Negative Breast Cancer
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
In recent years, immune therapy has significantly altered the treatment landscape for various malignant tumors, including breast cancer.
- Trial name
- NCT06229067
- Testing
- Adebrelimab, Vinorelbine, Cyclophosphamide (tablet)
- Volunteers
- 182 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deep Brain Stimulation, Parkinson's Disease and Parkinsonism
Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD
Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by both motor and non-motor symptoms. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectively alleviates motor symptoms; however…
- Conditions
- Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder
- Trial name
- NCT06914466
- Testing
- Deep Brain Stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
Esophageal Squamous Cell Cancer
Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT07769866
- Testing
- Induction chemo-immunotherapy, Concurrent chemoradiotherapy (cCRT), maintenance immunotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- RenJi Hospital
Solid Carcinoma
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy
This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
- Trial name
- NIVO-FMT (NCT05533983)
- Testing
- fecal microbiota transplantation with Nivolumab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Asan Medical Center
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Renal Anemia, Peritoneal Dialysis (PD)
Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients
This is a prospective multicenter randomized controlled clinical study. The goal of this clinical trial is to learn if intravenous iron isomaltoside injection use is equally effective and safe for the treatment of renal anemia in…
- Trial name
- NCT06830941
- Testing
- Iron isomaltoside, Ferrous succinate
- Volunteers
- 124 people
- Sponsor
- Xie Jingyuan, MD
Liver Transplant Infection
Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen
Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an…
- Trial name
- NCT06718517
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Parkinson Disease(PD)
Rhythm Psychophysics With Parkinson's Patients
The goal of this interventional study is to understand how the rhythmic abilities of individuals in the early stages of Parkinson's Disease (PD) are impacted by their levels of dopamine.
- Trial name
- RPPD (NCT07647913)
- Testing
- Withholding Levodopa
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- McMaster University
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Biliary Tract Cancers
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment…
- Trial name
- NCT06564623
- Testing
- mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins